Tbit™ Blood Testing Platform

World's First Nanowire Biosensing Platform for concussion and other TBI

Delivers objective results in less than 90 seconds, identifying TBI and reducing unnecessary CT scans for concussion.

Point-of-care platform to detect and measure a panel of protein biomarkers released into the bloodstream after a Traumatic Brain Injury.

Unique and proprietary technology that offers:

  • Ultra-high sensitivity
  • Quantitative results in < 90 seconds
  • Single drop of whole blood
  • Multiplexing on a single cartridge
  • Easy-to-use, affordable, disposable cartridge
  • Point-of-care delivery
  • Adaptability to any biomarker panel

Not FDA approved and currently for research use only. Not for use in diagnostic procedures.

BioDirection is always searching for new opportunities. Contact us today with any questions or inquiries.